Skip to Content
MilliporeSigma
  • In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions.

In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions.

Toxicology letters (2014-12-03)
Seung Jun Lee, Jung Bae Park, Doyun Kim, Soo Hyeon Bae, Young-Won Chin, Euichaul Oh, Soo Kyung Bae
ABSTRACT

In the present study, we evaluated the inhibitory potentials of finasteride for the major human hepatic UDP-glucuronosyltransferases (UGTs) (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15) in vitro using LC-MS/MS by specific marker reactions in human liver microsomes (except for UGT2B15) or recombinant supersomes (UGT2B15). Of the seven tested UGTs, finasteride potently, selectively, and competitively inhibited UGT1A4-mediated trifluoperazine-N-glucuronidation in human liver microsomes with an IC₅₀ value of 11.5 ± 1.78 μM and Ki value of 6.03 ± 0.291 μM. This inhibitory potency was similar to that of hecogenin, a well-known inhibitor of UGT1A4. However, finasteride did not seem to inhibit any of the other six UGTs: UGT1A1, UGT1A3, UGT1A6, UGT1A9, UGT2B7, or UGT2B15. Similarly, finasteride markedly inhibited UGT1A4 activity in recombinant human UGT1A4 supersomes, with a Ki value of 6.05 ± 0.410 μM. In addition, finasteride strongly inhibited UGT1A4-catalyzed imipramine-N-β-D-glucuronidation. However, on the basis of an in vitro-in vivo extrapolation, our data strongly suggested that finasteride is unlikely to cause clinically significant drug-drug interactions mediated via inhibition of the hepatic UGT enzymes involved in drug metabolism in vivo.

MATERIALS
Product Number
Brand
Product Description

Supelco
Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material
Theophylline, European Pharmacopoeia (EP) Reference Standard
USP
Theophylline, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
4-Methylumbelliferone, ≥98%
Sigma-Aldrich
1-Naphthol, BioXtra, ≥99%
Sigma-Aldrich
1-Naphthol, ReagentPlus®, ≥99%
Sigma-Aldrich
Chenodeoxycholic acid
Sigma-Aldrich
Uridine, ≥99%
Sigma-Aldrich
Theophylline, anhydrous, ≥99%, powder
Sigma-Aldrich
Uridine, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Uridine, BioUltra, ≥99%
Propofol, European Pharmacopoeia (EP) Reference Standard
Chenodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
1-Naphthol, puriss. p.a., reag. Ph. Eur., ≥99% (GC)
Finasteride for peak identification, European Pharmacopoeia (EP) Reference Standard
Hymecromone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
2,6-Diisopropylphenol, 97%
Sigma-Aldrich
3′-Azido-3′-deoxythymidine, ≥98% (HPLC)
Sigma-Aldrich
Trifluoperazine hydrochloride, meets USP testing specifications
Sigma-Aldrich
Trifluoperazine dihydrochloride, ≥99%, powder
Sigma-Aldrich
Serotonin hydrochloride, powder
Sigma-Aldrich
Niflumic acid
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
Finasteride, ≥98% (HPLC), powder
Supelco
Chlorpropamide, analytical standard, ≥97%
Chlorpropamide, European Pharmacopoeia (EP) Reference Standard
Finasteride, European Pharmacopoeia (EP) Reference Standard
Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard
Trifluoperazine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material